Differential DNA methylation as measured in blood is a promising marker of bladder cancer susceptibility. However, previous studies have exclusively used post-diagnostic blood samples, meaning that observed associations may be markers of disease rather than susceptibility.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Genome-wide methylation was measured in pre-diagnostic blood samples, using the Illumina Infinium HumanMethylation450 Bead Array, among 440 bladder cancer cases with the transitional cell carcinoma (TCC) subtype and 440 matched cancer-free controls from the Women's Health Initiative (WHI) cohort. After normalization and probe filtering, we used conditional logistic regression models to test for associations between methylation measurements at 361,184 CpG sites and bladder cancer risk.
Increased methylation at cg22748573, located in a CpG island within the 5'-UTR/first exon of the CITED4 gene, was associated with an 82% decreased risk of bladder cancer after adjusting for race/ethnicity, smoking status, pack-years of smoking, and leukocyte cell profile and accounting for multiple testing (OR=0.18, q-value = 0.05). The result was robust to sensitivity analyses accounting for time between enrollment and diagnosis, race, tumor subtype, and secondhand smoke exposure.
While results need to be confirmed in additional prospective studies, differential methylation in CITED4, as measured in blood, is a promising marker of bladder cancer susceptibility.
Identification of biomarkers of bladder cancer susceptibility in easily accessible tissues may allow targeting of screening efforts so as to improve bladder cancer prognosis. This is particularly important among women, who tend to have poorer bladder cancer outcomes than men.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2018 Mar 14 [Epub ahead of print]
Kristina M Jordahl, Timothy W Randolph, Xiaoling Song, Cassandra L Sather, Lesley F Tinker, Amanda I Phipps, Karl T Kelsey, Emily White, Parveen Bhatti
School of Public Health, Department of Epidemiology, University of Washington., Biostatistics Program, Division of Public Health Sciences, Fred Hutch Cancer Research Institute., Division of Public Health Sciences, Fred Hutchinson Cancer Research Center., Genomics Resource, Fred Hutchinson Cancer Research Center., Division of Public Health Sciences, Cancer Prevention Program, Fred Hutchinson Cancer Research Center., Epidemiology Department and Public Health Sciences Division, University of Washington and Fred Hutchinson Cancer Research Center., Epidemiology and Pathology and Laboratory Medicine, Brown University., School of Public Health, Department of Epidemiology, Fred Hutchinson Cancer Research Center .